PTC Therapeutics more than doubles as Ataluren gets positive opinion

|About: PTC Therapeutics (PTCT)|By:, SA News Editor

PTC Therapeutics (PTCT) +119.2% premarket after the Committee for Medicinal Products for Human Use of the European Medicines Agency issues a positive opinion on PTCT's application for a conditional marketing authorization of its Ataluren muscular dystrophy treatment.

The news is a major upside surprise: Credit Suisse says a potential early EU approval for Ataluren has not been priced in to shares.

Others involved in Duchenne muscular dystrophy treatments also trade higher premarket: RNA +16%, SRPT +3%.